CLINICAL_TRIALS
trial_result
· 2022-03-25
Clinical Trial Update: Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) [Phase 3]
Summary
Phase 3 trial evaluating APL-2 for paroxysmal nocturnal hemoglobinuria has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Apellis Pharmaceuticals, Inc. | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Status: COMPLETED | Results posted: 2022-03-25